



BC Centre for Disease Control
An agency of the Provincial Health Services Authority

Immunization Programs and Vaccine
Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: January 29, 2014

Administrative Circular: 2014:02

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2 – Immunization Program
Section IX-Adverse Events Following Immunization and Section VII- Biological Products.**

Section IX- Adverse Events Following Immunization

Pediatric Vaccine Consultation Service:

This page has been added to provide immunizers with information on the Pediatric Vaccine Consultation Service offered at BC Children's Hospital. This service offers immunization consultation in concert with local health care providers for:

- children who have previous known adverse events following immunization (AEFI),
- children with underlying medical conditions and/or possible contraindications to immunization,
- children where a recommendation has been made not to immunize further, and
- children whose parents are vaccine hesitant (often as a result of a previous AEFI).

Appropriate children may be referred by their pediatrician or local medical health officer. Telehealth consultation or Travel Assistance is available for children who live outside of the lower mainland.

**Please add new page number: 4a
Dated: January 2014**

Please remove the Table of Contents for Section IX-Adverse Events Following Immunization dated February 2013 and replace with the enclosed updated Table of Contents dated January 2014.

Section VII- Biological Products

FLUMIST®

This page has been revised to allow for use of publicly funded FLUMIST® vaccine in those 18-59 years of age. Due to increased immunogenicity the preferred product for this age remains TIV, however FLUMIST® does meet acceptable immunogenicity standards and is approved for use in this age group by Health Canada.

It is expected that the publicly funded FLUMIST® program will return to pediatric-only indications in the 2014-2015 influenza season.

**Please remove page numbers 33a-c dated October 2013.
Please replace with page numbers 33a-c dated January 2014.**

Palivizumab (SYNAGIS™)

Please remove the page dated November 2012. This page was added as a temporary measure to provide a Decision Support Tool for nurses working within the Child Health BC RSV Immuno-Prophylaxis Program in 2012-2013. It is no longer required by this group.

Please remove page numbers 83-84 dated November 2012.

Please also remove the Table of Contents for Section VII – Biologicals Products dated January 2014 and replace with the enclosed updated Table of Contents section dated January 2014.

If you have any questions or concerns, please contact Brittany Deeter, Public Health Resource Nurse at telephone (604) 707-2577, fax (604) 707-2515 or by email at brittany.deeter@bccdc.ca

Sincerely,



Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:

Dr. Perry Kendall
Provincial Health Officer

Dr. Eric Young
Deputy Provincial Health Officer

Craig Thompson
Director, CD Prevention – Immunization

Warren O'Briain
Executive Director
Communicable Disease and Addiction Prevention

Page 2 of 2